

DR. ANNA LISA PICCIOLO-LEHRKE
Member of the Supervisory Board

In the Supervisory Board since: May 2022
Elected until: 2027

Career and Education

- Since 2008 Head of Global Business Development Neurology at UCB Pharma GmbH
- From 2006 Member of the Corporate Business Development of UCB Pharma GmbH
- Since 2005 working for the Business Development & Licensing Team of Schwarz Pharma AG
- As of 2000, work for the Technology Transfer Office at the German Cancer Research Center in Heidelberg
- Doctorate in cell and molecular biology at the German Cancer Research Center in Heidelberg
- Biology studies

Expertise

As Head of Business Development for Neurology at UCB, Dr. Picciolo-Lehrke has extensive knowledge in the development, in-licensing and acquisition of pharmaceutical products. Furthermore, she is very well connected with important partners and decision makers in the international and German pharmaceutical industry. In the past, when the company still belonged to the UCB Group, she played a decisive role in shaping the business in the area of business development through co-marketing agreements and in-licensing of Single Pill. The work of the Supervisory Board will benefit from this, particularly with regard to the planned growth of APONTIS PHARMA.

Memberships in Statutory Domestic Supervisory Boards and in Comparable Domestic and Foreign Supervisory Bodies of Business Enterprises:

- EIT Health Germany GmbH, Mannheim
- Board Observer Grin Therapeutics Inc.